Results 81 to 90 of about 19,420 (250)
Study protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation [PDF]
, 2013 PMCID: PMC3602285This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided ...Bullen, C, Howe, C, Laugesen, M, McRobbie, H, Parag, V, Walker, N, Williman, J +6 morecore +1 more sourceMachine Learning Classification of Smoking Behaviours—From Social Environment to the Prefrontal Cortex
Addiction Biology, Volume 30, Issue 8, August 2025.Applying machine learning to a 10‐year longitudinal cohort, this study identifies stable predictors of smoking status and cessation. By integrating multimodal data – including electrophysiological and neuropsychological measures – our models achieved high classification accuracy and retained meaningful predictive power, prospectively distinguishing ...Pablo Reinhardt, Norman Zacharias, Marinus Fislage, Justin Böhmer, Barbara Hollunder, Zala Reppmann, Anton Wiehe, Rebecca Rajwich, Nanne Dominick, Kerstin Ritter, Malek Bajbouj, Thomas Wienker, Jürgen Gallinat, Norbert Thürauf, Johannes Kornhuber, Falk Kiefer, Michael Wagner, Oliver Tüscher, Henrik Walter, Georg Winterer +19 morewiley +1 more sourceEfficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review
Brain and Behavior, Volume 15, Issue 7, July 2025.This systematic review synthesizes data from 26 studies (n = 3020) and 10 registered trials assessing the psychiatric effects of GLP‐1 receptor agonists (GLP‐1 RAs). Although evidence for substance use disorders was limited and mixed, GLP‐1 RAs showed modest‐to‐moderate benefits for mood symptoms, anxiety, and quality of life in comorbid conditions ...Shakila Meshkat, Corinna Di Luciano, Alyssa Swiderski, Gloria Li, Reinhard Janssen Aguilar, Benjamin T. Dunkley, Amy C. Reichelt, Yanbo Zhang, Andrew Greenshaw, Eric Vermetten, Rakesh Jetly, Satya Dash, Sri Mahavir Agarwal, Jennifer Swainson, Venkat Bhat +14 morewiley +1 more sourceEffects of Lactobacillus fermentum GKF3 on Reducing Smoking and Brain Neurotransmitter Levels: Findings From Animal and Human Studies
Food Frontiers, Volume 6, Issue 4, Page 2065-2075, July 2025.1.Developing food‐grade probiotic strains with smoking reduction benefits presents a safer and more holistic health strategy.
2.An animal study demonstrated that L. fermentum GKF3 gavage elevated brain dopamine and serotonin levels.
3.A randomized controlled trial showed that L.You‐Shan Tsai, Shan Lin, Chin‐Chu Chen, Chun‐Hung Chiu, Mei‐Chin Mong, Shu‐Ling Hu, Chi‐Hao Wu +6 morewiley +1 more sourceGenetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo‐Controlled Trial
Clinical pharmacology and therapy, 2020 It is unclear if genetic variants affect smoking cessation treatment response. This study tested whether variants in the cholinergic receptor nicotinic alpha 5 subunit (CHRNA5) predict response to smoking cessation medication by directly comparing the ...Li-Shiun Chen, T. Baker, J. Miller, M. Bray, Nina Smock, Jingling Chen, Faith Stoneking, R. Culverhouse, N. Saccone, Christopher I. Amos, R. Carney, D. Jorenby, L. Bierut +12 moresemanticscholar +1 more sourceLight‐Activated Pharmacological Tools for Exploring the Cholinergic System
Medicinal Research Reviews, Volume 45, Issue 4, Page 1251-1274, July 2025.ABSTRACT
Cholinergic transmission plays a critical role in both the central and peripheral nervous systems, affecting processes such as learning, memory, and inflammation. Conventional cholinergic drugs generally suffer from poor selectivity and temporal precision, leading to undesired effects and limited therapeutic efficacy. Photopharmacology aims to Alessio Colleoni, Giulia Galli, Clelia Dallanoce, Marco De Amici, Pau Gorostiza, Carlo Matera +5 morewiley +1 more sourceEffects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.
Alcoholism: Clinical and Experimental Research, 2020 BACKGROUND
The alcohol cue reactivity paradigm is increasingly used to screen medications for the treatment of alcohol use disorder (AUD) and other substance use disorders.R. Miranda, S. O'Malley, Hayley Treloar Padovano, R. Wu, Daniel E. Falk, Megan L. Ryan, J. Fertig, Thomas Chun, Srinivas B. Muvvala, R. Litten +9 moresemanticscholar +1 more sourceNicotinic receptors [PDF]
, 2014 Regulation of normal or abnormal behaviour is critically controlled by the central serotonergic systems. Recent evidence has suggested that serotonin (5-HT) neurotransmission dysfunction contributes to a variety of pathological conditions, including ...A Auclair, A Beyeler, A Coppen, A Dahlstrom, A Fletcher, A Fletcher, A Gobert, A Jain, A Markou, A Pazos, AC Farley, AJ Grottick, AJ Grottick, AM Batman, AS Brown, AV Prochazka, B Chang, B Lendvai, BB Brodie, BL Jacobs, BM Twarog, BR Cooper, C Cirillo, C Nocjar, C Reperant, CP Müller, D Herve, D Hoyer, D Hoyer, D Kooy van der, D Quarta, DE Nichols, DJ Balfour, DJ Hayes, DL Murphy, DL Willins, DM Tomkins, DV Herin, E Costa, E Esposito, E Quattrocki, EB Ribeiro, EC Azmitia, ED Levin, ED Levin, EJ Bockstaele Van, EJ Bockstaele Van, EJ Mills, F Jenck, G Chevalier, G Chiara Di, G Cucchiaro, G Cucchiaro, G Engberg, G Giovanni Di, G Giovanni Di, G Giovanni Di, G Giovanni Di, G Giovanni Di, G Giovanni Di, G Giovanni Di, G Giovanni Di, G Porras, G Porras, GA Higgins, GA Higgins, GA Higgins, GA Kennett, GA Kennett, GF Koob, GW Dalack, H Khalki, H Moukhles, H Rollema, H Rollema, H Rollema, H Takahashi, HD Mansvelder, J Arnt, J Dong, J Hannon, JA Ascher, JE Anderson, JE Slemmer, JF Cryan, JH Thompson, JK Abrams, JL Neisewander, JR Martin, JW Coe, K Guillem, K Touiki, KD Alex, KG Baker, KH Thomas, KJ Clemens, KL Summers, L Galindo-Charles, L Pozzi, LA Pockros, LL McMahon, M Bubser, M Costa, M Dols, M Giorgetti, M Pierucci, M Pompeiano, M Reuben, M Zaniewska, M Zaniewska, M Zaniewska, MD Doherty, ME Benwell, MF O'Neill, MJ Bubar, MJ Bubar, MJ Eisenberg, MJ Millan, MM Rapport, N Corvaja, N Maurice, NA Rigotti, NB Edwards, NG Schneider, NM Barnes, OT Phillipson, P Deurwaerdere De, P Deurwaerdere De, P Enkhbaatar, P Olausson, P Olausson, P Seth, PA Crooks, PBS Clarke, PH Hutson, PJ Fletcher, PJ Fletcher, PJ Fletcher, PJ Kenny, PJ Kenny, PM Whitaker-Azmita, RD Schwartz, RF Mucha, RM Bowker, RM Bowker, RS Bitner, RS Bitner, S Hjorth, S Mihailescu, S Navailles, S Prisco, SG Matta, SJ Bonasera, SM Hall, SM Hall, SP Ji, SP Ranade, TA Shahan, V Cornea-Hébert, V Erspamer, V Hillegaart, V Matteo Di, V Matteo Di, V Matteo Di, V Matteo Di, V Matteo Di, V Matteo Di, V Matteo Di, W Feldberg, WA Corrigall, X Li, Y Takada, Z Ma, ZJ Yu +173 morecore +1 more sourceEmpirical Derivation and Prediction of Treatment Trajectories in Harmonized AUD Clinical Trial Datasets
Addiction Biology, Volume 30, Issue 7, July 2025.Using a data‐driven approach, we identified three clusters of alcohol consumption at the end of treatment for AUD that were associated with unique drinking trajectories and sex‐specific differences. We predicted these clusters using clinical feature data and highlight the utility of data‐driven methods for deriving AUD‐related phenotypes.Robert J. Kohler, Yasmin Zakiniaeiz, Terril L. Verplaetse, C. Leonardo Jimenez Chavez, MacKenzie R. Peltier, Hang Zhou, Sherry A. McKee, Walter Roberts +7 morewiley +1 more source
